374 related articles for article (PubMed ID: 35608635)
1. [Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].
Lauffer F; Biedermann T
Dermatologie (Heidelb); 2022 Jul; 73(7):520-528. PubMed ID: 35608635
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
4. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
J Dermatolog Treat; 2023 Dec; 34(1):2276043. PubMed ID: 38073228
[TBL] [Abstract][Full Text] [Related]
6. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
7. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
8. [Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches].
Müller S; Witte F; Ständer S
Dermatologie (Heidelb); 2022 Jul; 73(7):538-549. PubMed ID: 35925206
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
Sedeh FB; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2022 Aug; 102():adv00764. PubMed ID: 35818735
[TBL] [Abstract][Full Text] [Related]
10. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Narla S; Silverberg JI
Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
[No Abstract] [Full Text] [Related]
14. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
15. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Sun C; Su Z; Zeng YP
Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
[TBL] [Abstract][Full Text] [Related]
17. Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F; Malvaso D; Caldarola G; Simone C; Peris K; Chiricozzi A
Immunotherapy; 2023 Dec; 15(18):1521-1529. PubMed ID: 37850366
[TBL] [Abstract][Full Text] [Related]
18. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
20. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]